InflaRx Company
InflaRx and Beijing Defengrei Biotechnology (BDB) have a potentially first-in-class monoclonal anti-human complement factor C5a antibody in development for COVID-19 as well as inflammatory indications that include hydradenitis suppurativa, ANCA-associated vasculitis and Pyoderma Gangraenosum.
InflaRx on March 31 said it had enrolled the first patient into a randomized clinical trial in the Netherlands that is investigating the safety and efficacy of IFX-1 in patients with severe COVID-19-induced pneumonia. The patient is being treated at Amsterdam University Medical Centers, with additional centers in Germany and potentially other European countries planned.
InflaRx on March 31 said it had enrolled the first patient into a randomized clinical trial in the Netherlands that is investigating the safety and efficacy of IFX-1 in patients with severe COVID-19-induced pneumonia. The patient is being treated at Amsterdam University Medical Centers, with additional centers in Germany and potentially other European countries planned.
Technology:
COVID
Industry:
Treatments
Headquarters:
Germany
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership